For example, the identification of CRC preclinical models harboring HER2 overexpression due to gene amplification, and the results of anti-HER2 targeted treatment validated in both PDXs and XLs as a valuable tool for genotype-drug correlation studies that have already led to successful clinical trials [55, 56, 118]. The gene discussed is ERBB2; the disease is colorectal carcinoma.